Training neural circuits early in development improves response, study finds – University of Illinois News

CHAMPAIGN, Ill. When it comes to training neural circuits for tissue engineering or biomedical applications, a new study suggests a key parameter: Train them young.

Techniques for training engineered neural circuits usually involve training them after the cells have fully matured. Using light-sensitive neurons derived from mouse stem cells, researchers at the University of Illinois, Urbana-Champaign found that training them throughout early cell development and network formation led to lasting improvements in the connections, responsivity and gene expression of the resulting neural network. They published their results in the journal Scientific Reports.

Its like an old dog learning new tricks versus a young puppy, said graduate student Gelson Pagan-Diaz, the first author of the study. When were training a network, if we stimulate it when its still like a puppy, we can get a better response to the training than if it were already mature.

Improved neural training has many applications in bioengineering and regenerative medicine. For example, the Illinois team hopes to use trained neural circuits to control the movement and behavior of miniature bio-hybrid machines. The types of improvements yielded by early training could give the machines and circuits more functionality and give the researchers more precise control over those functions.

As we advance the field of building machines with living cells, being able to stimulate and program neuronal cells and networks with light early in their development could be an important tool in our engineering repository, said study leader Rashid Bashir, a professor of bioengineering and dean of the Grainger College of Engineering at Illinois. Furthermore, this work could have implications for developmental biology, regenerative medicine and brain research.

To train the neurons, the researchers used timed pulses of light to stimulate the cells. The researchers began the training regimen when the cells were early in their development clusters of stem cells, called embryoid bodies, primed to become motor neurons. They continued the training as the cells differentiated, becoming fully mature neurons, and further continued it after transferring the cells to plates to connect and form neural circuits.

They then compared the early trained circuits with those cultured first and trained later the usual method.

The researchers saw a number of differences between the groups, Pagan-Diaz said. In the neurons trained during development, they saw more extensions indicating connections between cells, an increase in neurotransmitter packages sent between cells, and more structured nerve firing, indicating greater network stability. The effects of the early training were long-lasting, whereas cells trained later tended to have transient responses.

You can think of the neurons being like athletes in training, Pagan-Diaz said. The light stimulation was like a regular workout for the neurons they were stronger and more athletic, and did their jobs better.

To determine the underlying basis for these changes, the researchers analyzed the neurons genetic activity. They saw an increase in gene expression for genes related to network maturity and neural function, indicating that the early training could have permanently altered genetic pathways as the cells developed, Bashir said.

The researchers are continuing to explore what kinds of activities could be enhanced or programmed by early neuron training in the embryoid body phase. Embryoid bodies could be useful building-block components for biological machines, Pagan-Diaz said, and also hold promise for regenerative medicine.

Previous studies have shown that embryoid bodies with motor neurons implanted into mice that had been injured could improve the regeneration of tissue, Pagan-Diaz said. If we can improve or enhance the functionality of these embryoid bodies prior to putting them into an injured model, then theoretically we could enhance the recovery beyond what has been seen with injecting them and then stimulating them later.

The National Science Foundation supported this work through the Emergent Behaviors of Integrated Cellular Systems science and technology center and through the Miniature Brain Machinery Research Traineeship. Research staffer Jenny Drnevich, graduate students Karla Ramos-Cruz and Richard Sam, and University of Illinois, Chicago bioengineering professor Perijat Sengupta were co-authors of the paper.

Link:

Training neural circuits early in development improves response, study finds - University of Illinois News

Global Genetic Engineering Vector Market Analysis Recent Trends And Regional Growth Forecast By Types And Applications 2020 – Bulletin Line

Global Genetic Engineering Vector Market Research Report Covers the existing situation and the development predictions of the industry for 2020. This Report has been prepared primarily based mostly on particular market assessment with inputs from industry experts. This estimated report consists of all have observed element about marketplace evaluation, increase Demand and forecast analysis in all over the world. This record gives a few edged examine and solution within the complicated international of polymer-based totally thermal interface materials market.

Key Players:- Company A And More

Genetic Engineering Vector market report describes the growth of the industry by upstream & downstream, the industry overall and development, key companies, as well as type segment & application and so on, and makes a scientific prediction for the development industry forecasts based on an analysis.

Get Sample Copy Of Report From Here and Get Instant 10% Discount : https://www.eonmarketresearch.com/sample/72606

Genetic Engineering Vector Market research report quantifies opportunities and Challenges to prioritize with the revenue. Then report explains each component thoroughly like business Strategies, Industry trends, Regional Development, Performance matrix. This vital data about Genetic Engineering Vector industry will help to improve market growth in terms of manufacturing capacity, Sales during the Forecast period of 2020.

Genetic Engineering Vector Market regional analysis covers the following regions: North America, Europe, Asia-Pacific, South America, Middle East & Africa.

The scope of the Report: This report focuses on the Genetic Engineering Vector in the global market, especially in Europe, North America, and Asia-Pacific, Middle East, and Africa, South America. This report describes the market based on regions, type, manufacturers, and application.

Buy This Premium Report: https://www.eonmarketresearch.com/buy/72606

Market Segment On The Basis Of Product Type Includes:-

General Type

Applications Mentioned In This Report:-

In Vitro StudiesClinical

The report then estimates 2020 market development trends of Genetic Engineering Vector market. Outline of upstream raw materials, downstream trade and prevailing market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Genetic Engineering Vector market before evaluating its feasibility.

This report presents an extensive analysis of the current Genetic Engineering Vector trends and emerging estimations & dynamics of the global Genetic Engineering Vector industry. Likewise, explains the comprehensive analysis of factors that drive and restrict the growth of the Genetic Engineering Vector market. Further covers a detailed analysis of the Genetic Engineering Vector industry based on type and application help in understanding the Genetic Engineering Vector trending products across geographies. Then highlights the potency of buyers and suppliers to understand the Genetic Engineering Vector market potency. Finally, an extensive analysis of the Genetic Engineering Vector market is conducted by key product positioning and monitoring of top players within the Genetic Engineering Vector market framework.

Place An Inquiry Before Investment @ https://www.eonmarketresearch.com/enquiry/72606

Table of Contents

1. Industry Overview of Genetic Engineering Vector2. Global Genetic Engineering Vector Competition Analysis by Players3. Company Profiles4. Global Genetic Engineering Vector Market Size by Type and Application (2020-2025)5. United States Genetic Engineering Vector Development Status and Outlook6. EU Genetic Engineering VectorDevelopment Status and Outlook7. Japan Genetic Engineering Vector Development Status and Outlook8. China Genetic Engineering Vector Development Status and Outlook9. India Genetic Engineering Vector Development Status and Outlook10. Southeast Asia Genetic Engineering Vector Development Status and Outlook11. Market Forecast by Regions, Type, and Application (2020-2025)12. Genetic Engineering Vector Market Dynamics13. Market Effect Factors Analysis14. Research Finding/Conclusion15. Appendix

**Thanks for reading this article; you can also get individual chapter wise section or region wise report version like United States, Europe, Middle East, and Africa or Asia-Pacific.**

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: [emailprotected]

Read the original:

Global Genetic Engineering Vector Market Analysis Recent Trends And Regional Growth Forecast By Types And Applications 2020 - Bulletin Line

Allow field trials of Bt brinjal to ensure safety of crops, agri-tech body writes to govt – ThePrint

Text Size:A- A+

New Delhi: The Alliance for Agri Innovation (AAI), a leading agri-tech industry body, has written to the central government and various states to allow field trials of Bt brinjal, a genetically-modified (GM) crop that was banned in 2010 following concerns raised about public health and biodiversity.

In a statement released Friday, the AAI said field trial was the only way to ensure safety of crops. blocking such trials amounts to blocking national development, it said.

AAIs letter has been sent to the agriculture ministry and chief ministers of Madhya Pradesh, Karnataka, Bihar, Chhattisgarh, Jharkhand, Tamil Nadu, Odisha and West Bengal.

The AAI statement also mentions how a 2019 peer-reviewed study had found that net returns to farmers from Bt brinjal crop averaged $2151/ha (Rs 1.61 lakh/ha) compared to $357/ha (Rs 26,768/ha) from non-Bt brinjal crop.

In India, Bt brinjal was cleared for commercial cultivation by the Genetic Engineering Appraisal Committee (GEAC) in 2009 but it was placed under an indefinite moratorium the following year by then minister of state for environment, Jairam Ramesh.

Several farmers from various states, including Maharashtra and Haryana, were found to be openly flouting the GM crop ban last year and sow Bt brinjal.

The crop has been commercially grown in Bangladesh since 2014 the first South Asian country to do so.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrints future.

SUBSCRIBE NOW

Also read: Why farmers are still having to protest for their right to sow GM seeds, even in a pandemic

Brinjal is an extremely pest-prone crop, and highly susceptible to the fruit and shoot borer (FSB) pest.

To reduce loss of yield, farmers often end up spraying this crop multiple times. A report from Bangladesh had earlier noted that protein in Bt brinjaldisrupts the digestive systems of certain pests, causing them to die within three days of ingestion.

It had also stated that advantages of using Bt brinjal over non-Bt brinjal were lower pest infection, higher yields, 56 per cent reduction in environmental toxicity and fewer complaints about symptoms consistent with pesticide exposure.

Ram Kaundinya, director general of AAI, said in the statement, The deadly FSB is a menace for farmers and its caterpillar also finds its way into our homes through infected brinjals. By controlling this with Bt technology, we can save farmers income, reduce pesticide load on the environment and provide pesticide- and insect-free brinjals to consumers.

AAI head Paresh Verma added, Development of indigenous technology is in line with the Atmanirbhar Bharat mission launched by Prime Minister Narendra Modi. Delays due to a paralysis in the decision-making process by the central and state governments have essentially stalled the progress in research to develop new technologies.

The AAI statement also noted how several studies and analyses into GM cultivation over the past 23 years have found no evidence of adverse health effects on humans or animals.

Also read: Now, Bangladesh set to steal march over India with GM rice that fights malnutrition

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And we arent even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrints future. It will take just a few seconds of your time.

Support Our Journalism

See the original post:

Allow field trials of Bt brinjal to ensure safety of crops, agri-tech body writes to govt - ThePrint

What to Watch When Twist Bioscience Reports Fiscal Q3 Results – Motley Fool

Uncertainty is one of the central themes of investing in 2020, but investors can be certain of one thing: Valuing shares of Twist Bioscience (NASDAQ:TWST) at more than 30 times sales is a little bit ridiculous.

The company's technology platform is intriguing, but it hasn't shown signs of becoming a commercial success from a business standpoint. In fact, Twist Bioscience has reported growing losses as it has scaled its business and relied on equity financing to fund operations. That hasn't stopped the small-cap stock from soaring by more than 200% since the beginning of 2020.

On the one hand, Twist Bioscience is uniquely positioned to help customers respond to the coronavirus pandemic. It has also signed a flurry of drug discovery deals this year. On the other hand, the financial impacts of those catalysts are a bit fuzzy. Here's what metrics investors will be watching when the company reports fiscal third-quarter 2020 operating results.

Image source: Getty Images.

Twist Bioscience is developing a DNA synthesis technology platform that can be used in drug discovery, genetic engineering experiments, and diagnostic panels. It's not necessarily the technological endgame, but it's the best we have right now. Heck, the company supplies many of its competitors with synthetic DNA.

And its technology platform looks to be playing an important role in the global response to the coronavirus pandemic. Twist Bioscience has created synthetic controls of the SARS-CoV-2 virus that can be used in diagnostic tests to detect whether a person is currently infected, launched SARS-CoV-2 antibody panels for research activities, and inked drug discovery deals with biopharmaceutical companies developing therapeutic antibodies to treat COVID-19.

Additionally, the company doesn't appear to have slowed future-oriented investments in its technology platform and businesses. Twist Bioscience has signed non-COVID-19 drug discovery deals with Takeda Pharmaceuticals, Seismic Bio, and Invetx (an animal health start-up) since the end of the fiscal second quarter of 2020.

The biggest question facing investors is pretty simple: Will announcements translate into tangible progress?

Investors are assuming Twist Bioscience will report a noticeable bump in quarterly revenue from coronavirus-oriented research tools, although financial details weren't disclosed for any of the drug discovery deals. The latter appear to be dependent on technology access fees and milestone or royalty payments, which wouldn't necessarily have a significant near-term impact.

Here's the problem: Even an incredible quarter probably isn't enough to make sense of the stock's current valuation. Investors shouldn't be paying 30 times sales for a money-losing business that has grown operating losses faster than gross profit and is entirely reliant on stock offerings to keep the lights on.

In other words, even a relatively strong quarter could cause the stock to drop. There's simply too much success baked into the company's market valuation right now. It's difficult to see how Twist Bioscience's $3 billion valuation is sustainable with publicly available information. Then again, it's 2020. Many stock valuations don't make much sense right now.

A great business is always a great investment in the long run, but a great investment is not always a great business. Thus far in 2020, Twist Bioscience has been a great investment, but the stock's ascension is detached from business fundamentals. That's likely to be true even with an amazing increase in revenue from the coronavirus pandemic, assuming that's what the results show. Investors might want to take that into account, as starting or adding to a position at current prices might sap long-term returns. Unless the company announces a major event that's not currently on investors' radar, it's simply difficult to see shares holding onto recent gains.

Here is the original post:

What to Watch When Twist Bioscience Reports Fiscal Q3 Results - Motley Fool

Viewpoint: Battling deadly disease with gene drives is worth the limited risk – Genetic Literacy Project

The fate of society rests in part on how humans navigate their complicated relationship with insects trying to save good insects and control bad ones. Some insects, like mosquitoes, bite people and make them sick remember Zika? Now the U.S. mosquito season is already in full swing, withover 10 cases of Dengue feverreported in the Florida Keys this year. Some insects, likebees, are pollinatorsthat help produce our food. Others, likelocusts, currently threaten cropsin East AfricaandAsia, preferring to eat our food instead.

Insects have proven themselves extremely capable at evolving strategies to get around control methods, such as chemical insecticides and habitat modification, and current pest control technologies are simply not keeping up.

We arebothinsect scientists. Our research has includedengineering a fungus to control malaria mosquitoes,uncovering the reproductive biology of honey bee workersand understanding thehealth impacts of invasive ticks. Weve come to appreciate the potential of emerging technologies like gene drive. This technology can guarantee that a trait will be inherited by the next generation. Such traits include making mosquitoesimmune to the malaria parasiteso they cannot spread the disease to humans.

Recently we contributed to astatement that advocates for continuing gene drive research. In light ofcalls for a moratorium, this statement recognizes that a ban on gene drive research would hamper a better understanding, and thus mitigation, of risks associated with this technology.

Moratoriums on gene drive technology have been called for and rejectedat the last twoUnited Nations Conventions on Biological Diversity. But there isa new push for a moratorium.

Gene drive is a technology that could allow society to control insects in a more targeted manner.

The general underlying principle of all gene drives is an organism that will produce offspring similar to themselves.

Some characteristics are randomly passed on from parents to the next generation. However, gene drive forces a different type of inheritance that ensures a specific characteristic is always present in the next generation. Scientists engineer gene drive using various molecular tools.

Gene drive is not just a human invention; some occur naturally in insects. For example, instalk-eyed flies, a gene on a sex-related chromosome causes any male fly to die without a certain gene cargo, including a gene that results in longer eyestalks. This type of genetic phenomenon has been well studied by scientists.

To date, gene drive has been discussed in the media primarilyin order to eradicate malaria. This may give you the impression that gene drive can be used onlyto drive mosquitoes to extinction. However, gene drive technologies are highly versatile and can be designed to bring about different outcomes. They can also be applied in most insect species that scientists can study in the laboratory.

Insects reproduce quickly and produce lots of offspring, which makes them obvious candidates for a technology that relies on inheritance like gene drive. This is why insects are at the leading edge of gene drive research. Gene drive is a new technology that could provide a solution to a variety of insect issues society faces today.

For instance, a gene drive has beendeveloped to stop a major crop pest, the spotted-wing Drosophila. Insecticide sensitivity could be spread through populations of this pest species to stoptens of millions of dollars in crop damage every yearin the United States.

Gene drive could also be a more targeted approach to stopping invasive insects, such as the infamousfire ant, from destroying native ecosystems. In the United States, millions of dollars have been spent onremoving fire ants using techniques including chemical insecticides, but if these persistent ants are not completely eradicated, they invade again.

Aside from how good insects are at circumventing our strategies to control them, another major struggle for controlling insects is finding them. Insects have evolved to quickly find the opposite sex to mate, and gene drives, which are passed on by mating, can take advantage of this fact of insect life. This also means this technology targets only the intended species, which is not the case for chemical insecticides currently in use.

Insect scientists, inspired by natural examples of gene drive, have wanted to design gene drive in insects for decades. Only recently have new molecular tools, such as the gene editing toolCRISPR-Cas, made the gene drive dream a reality. For now, gene drive insectslive in laboratories and none has been released into the wild. Still, a lot can be learned about how gene drive works while it is safely contained in a laboratory.

Using gene drive is not a universally popular idea. Criticisms tend to fall into three categories: ethical concerns, mistrust of technology and unintended ecological consequences.

Ethical concerns about gene drive are often motivated by larger issues, such as how to stop gene drive from being used in biological weapons by engineering insects that are more dangerous. Then there is the question of who should decide which gene drive projects move forward and what types of insects with gene drive can be released into the environment. These questions cant be answered by scientists alone.

Societal mistrust of technologyis a hurdle that some powerful, innovative technologies must overcome for public acceptance. The issue of technological mistrust often stems from disagreements about who should be developing technology to control insects and for what purposes.

The third common argument against gene drive technologies is that they might cause unintended consequences in the ecosystem because gene drive is designed by humans and unnatural. What will happen to the natural ecosystem if a population, even of mosquitoes that make people sick, is driven to extinction? Will this cause threats to natural biodiversity and the security of food? These questions are ultimately asking the consequences of intervening in the natural order of the world. But who defines what is the natural state of an ecosystem?Ecosystems are already constantly in flux.

When a gene drive is developed, it is tailored to the needs of a particular situation. This means theanticipated risksposed by each gene drive are project-specific and should be considered and regulated on a case-by-case basis. A responsible way to protect society from these risks is to advocate for continued research that enables scientists to describe and find solutions to them. Beyond the science, regulatory and accountability systems are needed so that regulations are adhered to and public safety is protected.

Researchers are also still exploring the science underlying the gene drive. Can gene drive be designed to be reversible or more efficient? Can the effect of a gene drive on an ecosystem be predicted? Such important unanswered questions are why even the most ardent supporters of this technology say more research is needed. Society needs new tools to control insect pests and protect ecosystems, and gene drive promises to augment our toolbox.

Isobel Ronai is an Endeavour Postdoctoral Research Fellow at Columbia University. Follow her on Twitter @IsobelRonai

Brian Lovett is a postdoctoral researcher at the Division of Plant and Soil Sciences at West Virginia University working on fungal biology and biotechnology. Follow him on Twitter @lovettbr

This article was originally published at the Conversation and has been republished here with permission. Follow the Conversation on Twitter @ConversationUS

Read the original here:

Viewpoint: Battling deadly disease with gene drives is worth the limited risk - Genetic Literacy Project

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 – Stockhouse

Key Highlights:

WILLIAMSVILLE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (22nd Century” or the Company”), a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding, today reported results for the second quarter ended June 30, 2020.

Despite the unprecedented challenges brought on by COVID-19, I am pleased to report net sales revenue of $6.4 million for the second quarter of 2020, up 11% from the prior year, continued gross profit margin expansion, and improved operating loss. These results demonstrate our ability to execute on our initiatives to improve our margins and cost structure. Our financial position remains strong and we will continue to operate with strict cost controls, allocate our resources efficiently, and deploy capital where we believe it will give us the greatest return on our investments,” said James A. Mish, Chief Executive Officer of 22nd Century Group.

With the comment period now closed on our Modified Risk Tobacco Product Application, the team is laser focused on setting the stage for a successful VLN® launch upon the authorization of our MRTP Application by the FDA. I am exceedingly proud of the dedication and tremendous progress the team has made so far this year and believe we are well positioned to capitalize on the many opportunities ahead,” Mish added.

Business Highlights and Notable Events:

COVID-19 Update

2020 Second Quarter and Year-to-Date Financial Results

Balance Sheet and Liquidity

Second Quarter Earnings Conference Call 22nd Century will host an audio-only webcast today at 8:00 a.m. ET to discuss the Company’s second quarter 2020 financial results.

The live audio webcast will be accessible in the Events section on the Company's Investor Relations website at http://www.xxiicentury.com/investors/events. An archived replay of the webcast will also be available shortly after the live event has concluded.

About 22nd Century Group, Inc. 22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content tobacco cigarettes containing 95% less nicotine than conventional cigarettes to adult smokers in the U.S. and international markets. The Company’s primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with valuable cannabinoid profiles and agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.

Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.

Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements concerning our business, operations and financial performance and condition as well as our plans, objectives and expectations for our business operations and financial performance and condition that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. You can identify these statements by words such as aim,” anticipate,” assume,” believe,” could,” due,” estimate,” expect,” goal,” intend,” may,” objective,” plan,” potential,” positioned,” predict,” should,” target,” will,” would” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management's beliefs and assumptions. These statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All forward-looking statements are subject to risks and uncertainties and others that could cause actual results to differ materially from those contained in our forward-looking statements. Please refer to the Risk Factors” in our Annual Report on Form 10-K filed on March 11, 2020 and in our subsequently filed Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law

Adjusted EBITDA, which the Company defines as earnings before interest, taxes, depreciation and amortization, as adjusted by the Company for certain non-cash and non-operating expenses, as well as certain one-time expenses, is a financial measure not prepared in accordance with generally accepted accounting principles (GAAP”). In order to calculate Adjusted EBITDA, the Company adjusts the net (loss) income for certain non-cash and non-operating income and expense items listed in the table above in order to measure the Company’s operating performance. The Company believes that Adjusted EBITDA is an important measure that supplements discussions and analysis of its operations and enhances an understanding of its operating performance. While management considers Adjusted EBITDA to be important, it should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating loss, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company’s measurement of Adjusted EBITDA may not be comparable to those of other companies.

Below is a table containing information relating to the Company’s Adjusted EBTIDA for the three and six months ended June 30, 2020 and 2019, including a reconciliation of net (loss) income to Adjusted EBTIDA for such periods.

Contacts: Mei Kuo 22nd Century Group (716) 300-1221 mkuo@xxiicentury.com

John Mills ICR (646) 277-1254 john.mills@icrinc.com

Deirdre Thomson ICR (646) 277-1283 deirdre.thomson@icrinc.com

See the original post:

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 - Stockhouse

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 – GlobeNewswire

Key Highlights:

WILLIAMSVILLE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (22nd Century or the Company), a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding, today reported results for the second quarter ended June 30, 2020.

Despite the unprecedented challenges brought on by COVID-19, I am pleased to report net sales revenue of $6.4 million for the second quarter of 2020, up 11% from the prior year, continued gross profit margin expansion, and improved operating loss. These results demonstrate our ability to execute on our initiatives to improve our margins and cost structure. Our financial position remains strong and we will continue to operate with strict cost controls, allocate our resources efficiently, and deploy capital where we believe it will give us the greatest return on our investments, said James A. Mish, Chief Executive Officer of 22nd Century Group.

With the comment period now closed on our Modified Risk Tobacco Product Application, the team is laser focused on setting the stage for a successful VLN launch upon the authorization of our MRTP Application by the FDA. I am exceedingly proud of the dedication and tremendous progress the team has made so far this year and believe we are well positioned to capitalize on the many opportunities ahead, Mish added.

Business Highlights and Notable Events:

COVID-19 Update

2020 Second Quarter and Year-to-Date Financial Results

Balance Sheet and Liquidity

Second Quarter Earnings Conference Call22nd Century will host an audio-only webcast today at 8:00 a.m. ET to discuss the Companys second quarter 2020 financial results.

The live audio webcast will be accessible in the Events section on the Company's Investor Relations website at http://www.xxiicentury.com/investors/events. An archived replay of the webcast will also be available shortly after the live event has concluded.

About 22nd Century Group, Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. The Companys primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content tobacco cigarettes containing 95% less nicotine than conventional cigarettes to adult smokers in the U.S. and international markets. The Companys primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with valuable cannabinoid profiles and agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.

Learn more atxxiicentury.com, on Twitter@_xxiicenturyand onLinkedIn.

Cautionary Note Regarding Forward Looking StatementsThis press release contains forward-looking statements concerning our business, operations and financial performance and condition as well as our plans, objectives and expectations for our business operations and financial performance and condition that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. You can identify these statements by words such as aim, anticipate, assume, believe, could, due, estimate, expect, goal, intend, may, objective, plan, potential, positioned, predict, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management's beliefs and assumptions. These statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All forward-looking statements are subject to risks and uncertainties and others that could cause actual results to differ materially from those contained in our forward-looking statements. Please refer to the Risk Factors in our Annual Report on Form 10-K filed on March 11, 2020 and in our subsequently filed Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law

Adjusted EBITDA, which the Company defines as earnings before interest, taxes, depreciation and amortization, as adjusted by the Company for certain non-cash and non-operating expenses, as well as certain one-time expenses, is a financial measure not prepared in accordance with generally accepted accounting principles (GAAP). In order to calculate Adjusted EBITDA, the Company adjusts the net (loss) income for certain non-cash and non-operating income and expense items listed in the table above in order to measure the Companys operating performance. The Company believes that Adjusted EBITDA is an important measure that supplements discussions and analysis of its operations and enhances an understanding of its operating performance. While management considers Adjusted EBITDA to be important, it should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating loss, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Companys measurement of Adjusted EBITDA may not be comparable to those of other companies.

Below is a table containing information relating to the Companys Adjusted EBTIDA for the three and six months ended June 30, 2020 and 2019, including a reconciliation of net (loss) income to Adjusted EBTIDA for such periods.

Contacts:Mei Kuo22nd Century Group(716) 300-1221mkuo@xxiicentury.com

John MillsICR(646) 277-1254john.mills@icrinc.com

Deirdre ThomsonICR(646) 277-1283deirdre.thomson@icrinc.com

Continued here:

22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020 - GlobeNewswire

Genetic Engineering Market Growing Popularity and Emerging Trends in the with Key Players 2027 – eRealty Express

The global Genetic Engineering Market, which is extensively assessed in the report contemplates the best need development angles and how they could affect the market over the figure residency under thought. The experts have taken careful endeavors to thoroughly evaluating every development factor of the market, other than indicating how certain market restrictions could represent a danger to players in the coming years. In addition, the report additionally gives data on top patterns and openings and how players could take advantage of them to take up the difficulties in the Genetic Engineering Market. This could be a helpful rule for players to concrete their situation in the business or make a rebound in the market.

The Leading Market Players Covered in this Report are : Integrated DNA Technologies, IncThermo Fisher Scientific Inc, Merck KGaA, Horizon Discovery Group Plc, .Transposagen Biopharmaceuticals Inc., New England Biolabs, Genscript Biotech Corporation, Lonza Group, Origene Technologies, Inc., Sangamo Therapeutics, Inc.

Get Sample PDF Of Genetic Engineering Market @ https://www.theinsightpartners.com/sample/TIPRE00004544

Impact of Covid-19 in Genetic Engineering Market:The utility-owned segment is mainly being driven by increasing financial incentives and regulatory supports from the governments globally. The current utility-owned Genetic Engineering are affected primarily by the COVID-19 pandemic. Most of the projects in China, the US, Germany, and South Korea are delayed, and the companies are facing short-term operational issues due to supply chain constraints and lack of site access due to the COVID-19 outbreak. Asia-Pacific is anticipated to get highly affected by the spread of the COVID-19 due to the effect of the pandemic in China, Japan, and India. China is the epic center of this lethal disease. China is a major country in terms of the chemical industry.

Genetic Engineering Market Regional Analysis Includes: Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe(Turkey, Germany, Russia UK, Italy, France, etc.) North America(the United States, Mexico, and Canada.) South America(Brazil etc.) The Middle East and Africa(GCC Countries and Egypt.)

Key Highlights of the Table of Contents:Genetic Engineering Market Study Coverage:It includes key market segments, key manufacturers covered, the scope of products offered in the years considered, global Genetic Engineering market and study objectives. Additionally, it touches the segmentation study provided in the report on the basis of the type of product and applications.Genetic Engineering Market Executive summary:This section emphasizes the key studies, market growth rate, competitive landscape, market drivers, trends, and issues in addition to the macroscopic indicators.Genetic Engineering Market Production by Region:The report delivers data related to import and export, revenue, production, and key players of all regional markets studied are covered in this section.Genetic Engineering Market Profile of Manufacturers:Analysis of each market player profiled is detailed in this section. This segment also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy Premium Report @https://www.theinsightpartners.com/buy/TIPRE00004544

Key Questions Answered: To gain insightful analyses of the Genetic Engineering market and have a comprehensive understanding of the global market and its commercial landscape. Assess the production processes, major issues, and solutions to mitigate the development risk. To understand the most affecting driving and restraining forces in the market and its impact on the global Genetic Engineering market. Learn about the Genetic Engineering market strategies that are being adopted by leading respective organizations. To understand the future outlook and prospects for the market. Besides the standard structure reports, we also provide custom research according to specific requirements.

For More Information Kindly Contact: Tel: +1-646-491-9876

Email: [emailprotected]

Read more here:

Genetic Engineering Market Growing Popularity and Emerging Trends in the with Key Players 2027 - eRealty Express

Plants Have Hormones, Too, and Tweaking Them Could Improve Food Supply – Scientific American

Between crop damage caused by climate changeand a rising global population and nutritional demand, it is clear the world will need to produce more food in the future. Researchers have long studied ways to help plants resist environmental stressors such as pests and drought, both through conventional breeding and genetic modification. But many questions still remain about how, exactly, plants interact with their environment and how scientists might be able to modify those processes to help them adapt.

Researchers at the Institute of Network Biology in Germany and their colleagues may have found a way to help. In early July they published a study in Nature showing that plants communicate with the environment in more complex ways than previously thought. The investigation revealed that the information-processing network, driven by hormones, in one genus of plants is carried out by more than 2,000 protein interactions, hundreds of which had not been discovered before. Were going to need a second green revolution, says Shelley Lumba, a plant biologist at the University of Toronto, who was not involved in the study. These would be good leads to test.

Unlike animals, which complete most of their development in utero, plants remain relatively flexible throughout their life. Sensory proteins detect changing environmental conditions and then use hormones to cause it to alter its behavior or physiology accordingly. Many pathways are well understood: the hormone ABA, for instance, tells plants to close their pores and conserve water during drought by directing a series of specific proteins to carry out cellular functions.

The flexibility of these hormone networks is precisely what has made them so difficult to genetically modify or engineer to cope with changing climates, however. Most genetically modified crops that are on the market are made by adding a gene from bacteria to a plants genomeallowing it to resist an herbicide or insecticide, for example. And although the alternative, manipulating proteins, is relatively easy with new genome-editing techniques, you usually mess up the plants, says Eilon Shani, a plant biologist at Tel Aviv University.

To create crops that resist environmental stressors, researchers have relied on conventional breeding techniques using the genetic diversity that exists naturally among them. They have done so to develop varieties of wheat that produce high levels of ABA, for instance. That sort of breeding has become increasingly difficult in recent years, says Matthew Hudson, a crop scientist at the University of Illinois at Urbana-Champaign. For one thing, many countries have begun banning the export of seeds that have useful properties in order to conserve them as a natural resource.

New technologies, including CRISPR/Cas9 genome editing, can make genetic modification relatively straightforward. Scientists hoping to tweak plant genes must first know what they are looking for, however. Focusing on systems rather than individual genes could prove useful. To activate their defenses against insects, for example, plants might have to shut down another hormone pathway, such as growth or water conservation.

There are a lot of trade-offs that are fundamental to plant physiology, and we know they're there, but theyre not characterized in a quantitative way, Hudson says. Research such as the Nature study, he says, could help scientists develop computational models that would reveal how to understand and tweak the pathways through genetic engineering. This is obviously the next generation of research, Hudson says.

Making plants more flexible might be more important than giving them specific traits. Hormones permit responses to take place, Lumba says. Theyre not instructing; theyre allowing environmental stimulation to be read.

Lumba is studying the hormone mechanisms that help certain plants quickly repopulate areas razed by forest fires. When these fire followers sense the chemicals emitted from burned materials, they release a hormone called auxin that sparks germination. Yet because all known plants contain auxin, as well as the smoke-sensing proteins, it remains unclear why most of them do not actually respond. Mapping out the extensive pathways between the sensor and the response, she says, could be a step toward helping restore ecosystems after a fire.

Creating crops that quickly adapt to their environments will continue to be a massive endeavor. Most plant researchers studying signaling mechanisms have focused on Arabidopsis, a genus of small flowering herbs related to cabbage and mustard. A laboratory model of Arabidopsis has been extremely well characterized. Revealing the entire network of protein interactions in crops such as corn or rice, Hudson says, would take years and millions of dollars.

Although researchers have been working on genetically modified crop plants that resist drought or other stressors, none of the variations are close to being commercially available. We have transgenic traits we can add on top [of conventionally bred plants], but were really not engineering the subtle things that make plants into viable crops, Hudson says. His group and others at the University of Illinois are working on developing computer algorithms to predict how modifying particular genes through engineering would affect a plants growth. For slow-growing organismsincluding walnut trees, which are under threat from a parasitic fungussuch a system could save many years of watching and waiting.

The same advantage is true for noncrop plants. Bingru Huang, a plant biologist at Rutgers University, has genetically modified hormone-signaling pathways in grasses used for golf-course turf and other applications. Increasing the amount of hormones called cytokinins and making the plants more sensitive to their changing levels, she found, made the grasses more resistant to heat and salty soil. Huang says practical genetic engineering of hormone pathways will be difficult, however. When you change one hormone, others change, she adds.

Ultimately, figuring out the ways plants communicate with their surroundings and adapt to harsh environments could benefit the food supply. We dont think were smarter than nature and smarter than plants, Shani says. But we might help plants adapt faster than waiting another million years for evolution to do its work again.

View original post here:

Plants Have Hormones, Too, and Tweaking Them Could Improve Food Supply - Scientific American

Novartis says CAR-T cancer therapy works in second lymphoma type – BioPharma Dive

Dive Brief:

Three years on from Kymriah's pioneering approval as the first CAR-T cell treatment, the drug remains a relatively niche product, used for leukemia and lymphoma patients whose cancers have resisted other treatments.

But Novartis, as well as its CAR-T competitor Gilead, have continued to study their therapies in new cancer types as well as in earlier lines of treatment.

Gilead, which sells Yescarta for diffuse large B-cell lymphoma, recently won U.S. approval for Tecartus, a slightly different version of Yescarta that is now cleared for treating patients with mantle cell lymphoma.

Sales of both Yescarta and Kymriah have grown steadily, although neither is yet the blockbuster product their respective makers made them out to be when they were approved.

Ned Pagliarulo / BioPharma Dive, sales data from companies

CAR-T therapies have shown dramatic effectiveness in some patients with few other options. But the treatments are difficult to manufacture, requiring the genetic engineering of immune cells extracted from each patient. Manufacturing is done at several sites scattered throughout the U.S. and Europe, meaning cells must be carefully frozen and shipped from treating hospitals to company plants and back.

Remarkably, neither Novartis nor Gilead have missed a delivery of their respective CAR-T treatments due to the COVID-19 pandemic, according to recent executive comments on earnings calls.

Novartis, which has struggled to produce Kymriah at the correct commercial specifications, has had its manufacturing task made easier by the recent regulatory clearances of factories in Switzerland and France.

The Swiss company plans to submit data from the ELARA trial to the Food and Drug Administration and the European Medicines Agency in 2021. Detailed results will be shared at an upcoming medical meeting, likely the American Society of Hematology's now virtual conference in December.

After diffuse large B-cell, follicular lymphoma is the second most common type of non-Hodgkin lymphoma. Recent approved treatments include Verastem Oncology's Copiktra and Bayer's Aliqopa.

Link:

Novartis says CAR-T cancer therapy works in second lymphoma type - BioPharma Dive

Critical Recurring Mutation Identified in Head and Neck Cancers – Genetic Engineering & Biotechnology News

Scientists at the University of California-San Diego report that an investigational drug candidate called tipifarnib showed promise in treating head and neck squamous cell carcinoma (HNSCC) tumors with mutations in the HRAS gene. Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, and squamous cell carcinomas account for the majority of these cases.

The study Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas, published in Molecular Cancer Therapeutics, findings shed new light on the HRAS gene, a member of the RAS family of genes that produce proteins that regulate a variety of cellular processes, including growth, movement and differentiation. In 4 to 8 percent of HNSCC tumors, the HRAS gene is mutated.

Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational attachment of farnesyl groups to signaling proteins that are required for localization to cell membranes. Although all RAS isoforms are FT substrates, only HRAS is exclusively dependent upon farnesylation, raising the possibility that HRAS mutant tumors might be susceptible to tipifarnib-mediated inhibition of FT, write the investigators.

Here, we report the characterization of tipifarnib activity in a wide panel of HRAS mutant and wild type HNSCC xenograft models. Tipifarnib treatment displaced both mutant and wild type HRAS from membranes but only inhibited proliferation, survival and spheroid formation of HRAS mutant cells. In vivo, tipifarnib treatment induced tumor stasis or regression in all six HRAS mutant xenografts tested but displayed no activity in six HRAS wild type PDX models.

Mechanistically, drug treatment resulted in reduction of MAPK pathway signaling, inhibition of proliferation and induction of apoptosis and robust abrogation of neovascularization, apparently via effects on both tumor cells and endothelial cells. Bioinformatics and quantitative image analysis further revealed that FT inhibition induces progressive squamous cell differentiation in tipifarnib-treated HNSCC PDX.

These preclinical findings support that HRAS represents a druggable oncogene in HNSCC through FT inhibition by tipifarnib, thereby identifying a precision therapeutic option for HNSCCs harboring HRAS mutations.

This preclinical research has the potential to extend to the entire HNSCC patient community, whose overall survival rates are limited in recurrent or metastatic disease, and existing therapeutic options that are far from optimal, with response rates of roughly 10 to 20 percent, said senior co-author J. Silvio Gutkind, PhD, Distinguished Professor of Pharmacology and associate director of basic science at UC San Diego Moores Cancer Center.

These preclinical findings support the idea that HRAS represents a druggable oncogene in HNSCC through tipifarnibs inhibition of a key enzyme. It is a precision therapeutic option for HNSCCs harboring HRAS mutations.

In the study, UC San Diego researchers found that cell line- and patient-derived HNSCC models harboring HRAS mutations were highly sensitive to tipifarnib, which the authors said has demonstrated encouraging preliminary clinical activity in patients with relapsed or refractory HRAS-mutant HNSCC to date.

Currently, Kura Oncology, a San Diego-based biopharmaceutical company, is conducting a nationwide clinical trialto assess the safety and efficacy of tipifarnib in head and neck cancer with HRAS mutations. Employees of Kura are co-authors of the new paper. UC San Diego is not part of the trial.

Treatment with tipifarnib, wrote study authors, had a multifaceted effect on the biology of HRAS-mutant HNSCC tumors, reducing oncogenic signaling and proliferation, while increasing apoptosis, blocking angiogenesis, and driving squamous differentiation of tumors.

Head and neck cancer accounts for approximately 650,000 cases and 330,000 deaths annually worldwide. In the United States, approximately 4 percent of all cancers are head and neck, with an estimated 65,630 persons diagnosed each year, two-thirds of them men and 14,500 deaths, according to Cancer.Net.

Follow this link:

Critical Recurring Mutation Identified in Head and Neck Cancers - Genetic Engineering & Biotechnology News

Where FoodTech meets the plate: The 11 finalists of Calcalists Food Innovation Contest – CTech

Calcalists startup contest that aims to find the next great FoodTech innovation, in partnership with Tnuva, has reached its final stage. The team of judges together with accounting firm Somekh Chaikin, KPMG's member firm in Israel, has selected 11 leading companies among dozens of entries that will take part in the final event.

Amai Proteins

Founder: Ilan Samish

Investors: The Kitchen - FoodTech Hub, Israel Innovation Authority, Zora Ventures

Amai Proteins Ltd. produces sweet proteins as sweeteners and sugar substitutes, which it claims are tasty, cheap, and environmentally friendly.

The company produces designer proteins suitable for the food market when the sweetener being its first product, creating a healthier sugar substitute than those currently on the market. Although there are several companies in the field of sugar substitutes, the company has no competitors in the technology of designer proteins.

Robin Food

Founder: Shai Rilov

Investors: None provided

Robin Food is a non-profit that developed an app allowing its users to coordinate food transfers to avoid wasting resources, by sharing excess food between consumers and people in their community.

The company plans to expand tint cooperation between restaurants and users. For example, a restaurant that knows it has a supply of fish for the next few days can advertise on the app and offer discounts for users.

The final stage will be to connect organizations with commercial excess with aid organizations or other major bodies. The company currently operates a restaurant and catering service specializing in salvaged food waste.

Blue Tree Technologies

Founder: Yuval Klein

Investors: None provided

Blue Tree Technologies Ltd. is a sugar reduction platform for industrial applications in the drinks industry. Its objective is to selectively remove sugars from natural drinks without any addition of additives. its first product is pure sucrose-reduced orange juice.

The natural juices industry has been in decline for several years due to the high sugar found in them. Reducing sugar in natural juice will allow more people who have stopped consuming juices for health reasons to return to consuming them.

Blue Trees main competitor in Israel is Better Juice, which offers a similar product, but uses different technology.

SavorEat

Founders: Racheli Vizman, Oded Shosayev, and Ido Braslevsky

Investors: Israel Innovation Authority, private investors, Millennium Food-Tech

SavorEat Ltd. is developing a new generation of meat replacements. Its product combines 3D printing, automated cooking devices, and unique plant-based materials that allow it to create a variety of meat-like textures and designs.

The companys solution is designed to use infrared light to cook the burger as it prints, adjusting the serving to match the consumers specific dietary needs. The raw material the company uses does not necessitate refrigeration and is gluten and allergen-free.

The meat-substitute industry has been booming in recent years and Israel boasts several companies active in the space. SavorEats product stands out because it also offers the cooking process providing the user an end-to-end experience.

Verticanna

Investors: Israel Innovation Authority and Yoav Zeif

.

Verticanna claims that through the platform the company manages to produce one gram of medical cannabis at a cost of half a dollar compared to almost a dollar that it costs to produce today.

Trellis

Founder: Ilay Englard

Investors: None provided

Trellis, incorporated as ATPlabs Ltd. has developed an AI-powered food system intelligence platform to reduce food waste. The company says its product accurately forecasts crop production, supply chain fluctuations, and market trends, which can result in lower costs, improved quality, and reduced excess.

To achieve its forecasts, the company's system uses information available online, such as satellite imagery, and weather reports, and is connected to the customer's information systems. According to the company, it managed to save 10% in waste and increase productivity by 3% in the tomato-growing industry.

Tevel Aerobotics Technologies

Founder: Yaniv Maor

Investors: Maverick Ventures, OurCrowd, Ziv Aviram, Amichai Steimberg, Avi Gross, Eyal Desheh

Tevel Aerobotics Technologies has developed a drone with a robotic arm that allows farmers to determine which fruit is ripe and pick it. The drone offers convenient access to the fruit and gathers information about their quality, quantity, and fertilizer and water levels. The flying robot can move in six directions and works with all fruit varieties. The company aims to solve personnel shortages in agriculture.

Future Meat Technologies

Founders: Yaakov Nahmias and Eran Groner

Investors: S2G Ventures, Tyson Ventures, Emerald Technology Ventures, Manta Ray Ventures, Bits x Bites, Monde Nissin

Future Meat Technologies Ltd. is a biotechnology company that develops technology for the GMO-free production of meat directly from animal cells, without the need to raise or slaughter animals.

The company's technology is based on research conducted in the laboratory of Prof. Yaakov Nahmias, founder of the Center for Bioengineering at the Hebrew University of Jerusalem. The company is developing a technological platform for industrial-scale production that enables economical and scalable production of meat-free meat products, in order to free the world from animal dependence.

The technology simulates the fermentation processes of existing foods like yogurt or beer. Since its inception in 2018, the company has successfully created a bank of cells from various sources such as poultry and beef and adapted various formulas to create muscle and fat tissue.

BeeWise

Founder: Saar Safra

Investors: lool Ventures, Atooro Fund, ARC Impact, Beach investments, Fortissimo Capital

BeeWise Technologies Ltd. developed autonomous beehives that operate by utilizing AI-powered precision robotics and a network of cameras and sensors. The company's platform enables real-time detection and automated solution to 97% of the problems that may arise.

See original here:

Where FoodTech meets the plate: The 11 finalists of Calcalists Food Innovation Contest - CTech

WVU researcher to study THC levels in industrial hemp – WVNS-TV

MORGANTOWN, W.Va. (WBOY) A researcher at West Virginia University has received $200,000 from the U.S. Department of Agriculture to study industrial hemp for two years.

One of the many factors Michael Gutensohn, an assistant professor of horticulture in the Davis College of Agriculture, Natural Resources and Design, will be studying is the THC levels in hemp plants. THC is the psychoactive compound in hemp and cannabis that causes someone to get high and hemp growers are only allowed to have 0.3% of it in their plant. However, this is hard to control because very little is understood about the hemp plant since growing it was illegal until 2018.

If you look at hemp, theres very little [understood], but on the flip side of that, any grower that grows hemp has the same questions and issues as, say, someone who grows corn would have. Theres a huge gap in knowledge and we really need to do some research there and were almost decades behind some of these other crop systems.

Because very little is known about why hemp plants go hot, the term for when they exceed the 0.3 percent THC limit, growers often have to discard their harvest or wait and hope the concentration drops, according to a WVU press release. Gutensohn said this problem is far from rare and as a result growers are suffering, and in need of answers.

Those answers, he said, could lie in the fact that there are a variety of hemp plants, some of which are less prone to having higher THC percentages. Another avenue that might yield some answers is better understanding the environmental impacts on triggering THC. These environmental factors include soil conditions, pests, pathogens and the use of fertilizer among other things, all of which will be studied.

In general, the end goal is to hopefully gain knowledge that can be used to develop varieties, hemp varieties, that would not run into this problem anymore, Gutensohn said. And in principle, there are two avenues for that, either you can do classical breeding, where you just test many many different varieties and hope to find and breed some that dont run into that problem. Thats what has been done and is still be done by certain seed companies that breed hemp. The other thing that might be a different avenue and a little bit quicker to solve some of these problems is genetic engineering.

The real aim is to have answers for growers at the end of the two year period as to how they can avoid running into the problem of hot hemp. As his research starts producing more answers, Gutensohn said, that information will start to be disseminated through WVUs Extension Services that works with West Virginian farmers.

Developing new hemp varieties will take quite some time, Gutensohn said, because breeding and developing new seeds is a pretty lengthy process. That is why he is looking more in the short term to find answers.

Another aspect of Gutensohns research is beyond THC and looks at some of the many other chemical compounds found in the hemp plant. He said some are helpful in producing pharmaceutical products. One of those compounds is terpenes, which is what gives hemp and cannabis their unique smell.

They are basically a feedstock material that theres a lot of different interests in from the chemical industry, Gutensohn said. For flavors, fragrances, they are even, for example, considered as a biofuel or a biofuel additive. Theres a lot of interest in that, hemp plants produce an enormous amount of these compounds. Our research sort of looks at more than just THC and CBD, but a larger number of compounds because we hope that hemp can be sort of a platform to produce a lot of these compounds as well and our research will hopefully help from that perspective.

According to the release, for this project, Gutensohn is partnering with two former WVU faculty members Nik Kovinich, assistant professor of systems biology at York University and Nianqiang Wu, professor of chemical engineering at the University of Massachusetts Amherst.

More:

WVU researcher to study THC levels in industrial hemp - WVNS-TV

Global CRISPR Gene-Editing Market Future Growth Analysis, Business Demand and Opportunities to 2027 | Applied StemCell, ACEA BIO, Synthego, Thermo…

Global CRISPR gene-editing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the CRISPR gene-editing market for Global, Europe, North America, Asia-Pacific, South America, and the Middle East & Africa.

Global CRISPR Gene-Editing Market report performs systematic gathering, recording and analysis of data about the issues related to the marketing of goods and services and serves the businesses with an excellent market research report. The report provides intelligent solutions to complex business challenges and commences an effortless decision-making process. The report analyses and evaluates the important industry trends, market size, market share estimates, and sales volume with which industry can speculate the strategies to increase return on investment (ROI). In the Global CRISPR Gene-Editing Market document, the statistics have been represented in the graphical format for an unambiguous understanding of facts and figures.

CRISPR gene-editing marketis rising gradually with a healthy CAGR of 23.35 % in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth.

Get a Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crispr-gene-editing-market

Key Market Players:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global CRISPR Gene-Editing Market By Therapeutic Application (Oncology, Autoimmune/Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR/Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr/Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Global CRISPR Gene-Editing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the CRISPR Gene-Editing Industry

High prevalence of cancer worldwide is driving the growth of this marketJoint ventures by biotechnical companies for the advancement of genetic engineering for the development of CRISPR worldwide can also boost the market growthExpanding the application of CRISPR technology by innovative research from the different academic organizations also enhances the market growth

High finance in research and development also acts as a driving factor in the growth of this marketProbable mistreatment of CRISPR gene editing device and CRISPR/Cas genome editing device is restricting the growth for the marketScientific and major technical challenges for the production of disease specific novel CRISPR gene editing can also hamper the market growthLack of healthcare budget in some middle-income countries restricts the market growth

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-crispr-gene-editing-market

The titled segments and sub-section of the market are illuminated below:

By Therapeutic

OncologyAutoimmune/Inflammatory

By Application

Genome EngineeringDisease ModelsFunctional GenomicsOthers

By Technology

CRISPR/Cas9Zinc Finger NucleasesOthers

By Services

Design ToolsPlasmid and VectorCas9 and g-RNADelivery System ProductsOthers

By Products

GenCrispr/Cas9 kitsGenCrispr Cas9 AntibodiesGenCrispr Cas9 EnzymesOthers

By End-Users

Biotechnology & Pharmaceutical CompaniesAcademic & Government Research InstitutesContract Research OrganizationsOthers

Top Players in the Market are:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

How will the report help new companies to plan their investments in the CRISPR Gene-Editing market?

The CRISPR Gene-Editing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-crispr-gene-editing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: CRISPR Gene-Editing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: CRISPR Gene-Editing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Go here to read the rest:

Global CRISPR Gene-Editing Market Future Growth Analysis, Business Demand and Opportunities to 2027 | Applied StemCell, ACEA BIO, Synthego, Thermo...

Opinion | The US is belatedly facing up to the ugly truth about shifty China – Livemint

On 23 July, US secretary of state Mike Pompeo delivered a speech that is the clearest admission ever by a top US official that his countrys leadership had followed a wrong China strategy for half a century. And to say this, Pompeo chose the Richard Nixon Presidential Library and Museum as a venue. President Nixon began the current US-China relationship in 1971, after 22 years of hostility.

Pompeo said that US policymakers had presumed for decades that as China became more prosperous, it would open up, it would become freer at home, and indeed present less of a threat abroad". They had been totally mistaken. And if we dont act now," said Pompeo, ultimately the Chinese Communist Party (CCP) willsubvert the rules-based order that our societies have worked so hard to build. If we bend the knee now, our childrens children may be at the mercy of the CCP, whose actions are the primary challenge today in the free world."

Secretary of state Henry Kissinger visited China in 1971, and soon after, the US began providing financial and military assistance. In the late 1970s, Deng Xiaoping realized that to prosper, China needed to obtain knowledge and skills from the US, the key being technology. In 1979, Deng and President Jimmy Carter signed agreements that led to the US providing China, as analyst Michael Pillsbury put it, the greatest outpouring of American scientific and technological expertise in history". The next year, the US granted China most-favoured-nation status as a trading partner. Wrote Pillsbury in 2015: There is no available accounting of all the activities funded by the US government to aid China. Not only is America funding its chief opponent, it doesnt even keep track of how much is being spent to do it."

In the 1980s, the Ronald Reagan administration funded and trained new Chinese state-run institutes specializing in high-tech areas, from genetic engineering to intelligent robotics. US companies began investing in China, agreeing (or being coerced) to transfer often-proprietary technology to Chinese firms. Wall Street bankers grew mega-rich while raising billions of dollars for Chinese companies, many of them dubious, with very few following transparent accounting norms.

Americans paid no attention to the fact that Chinese textbooks continued to portray the US as a hegemon that, for more than 150 years, had tried to stifle Chinas rise. Or that the Chinese National Museum in Beijing, where the CCP tells its version of Chinese history, consistently shows America as an evil power. The list of anti-China US presidents showcased range from Abraham Lincoln (who surely didnt have much time to think about China) toincrediblyNixon. The US ignored Document 9, a 2013 CCP position paper that stated that the belief that freedom, democracy and human rights are universal" is an attack on the foundations of the CCP, and promoting Western constitutional democracy" is an attempt to undermine the socialism-with-Chinese-characteristics system of governance".

Soon after the terror attacks of 9 September 2001, The Telegraph of London reported that the Chinese state-run propaganda machine is producing books, films and video games glorifying the strikes as a humbling blow against an arrogant nation". The State-owned Beijing Television produced a documentary, Attack America, in which, over the video of the jets crashing into the World Trade Centre, the narrator says: This is the America the whole world has wanted to see. Blood debts have been repaid with blood." Yet, a mere three months after 9/11, China achieved its dream of admission to the World Trade Organization (WTO), principally due to strong US support. Since then, it has repeatedly flouted WTO rules.

The Peoples Liberation Armys (PLAs) cyber warfare division, Unit 6139, has been found to be hacking into vital US computer systems for years, from its department of defence to Google and AT&T, and stealing data and technology. The J-20, the PLAs answer to the American stealth fighter jet F-35, may have been developed with F-35 designs stolen from the US. But when Chinese President Xi Jinping visited the US in 2015, Barack Obama agreed to Chinese demands not to raise the issues of intellectual property theft and the PLAs cyber attacks.

Last month, Christopher Wray, director of the Federal Bureau of Investigation, described Chinese stealing of scientific research from US industry and academia as theft on a scale so massive that it represents one of the largest transfers of wealth in human history". In one case, Chinese scientist Hongjin Tan alone was found to have stolen over $1 billion worth of trade secrets from his employer, a petroleum company, before getting caught.

But none of this is a great revelation to any China watcher. These facts have been known for years, if not decades. The only mystery is why the US government took so long to wake up. As Pompeo put it, Perhaps we were naive about Chinas virulent strain of communism, or triumphalist after our victory in the Cold War, or cravenly capitalist, or hoodwinked by Beijings talk of a peaceful rise." Whatever the reason, it is good news for the world that America is finally facing the truth about Beijing.

Sandipan Deb is a former editor of Financial Express, and founder-editor of Open and Swarajya magazines

Subscribe to newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Continued here:

Opinion | The US is belatedly facing up to the ugly truth about shifty China - Livemint

Novartis Taps Sangamo Zinc Finger Tech for Gene Regulation Therapies – Genetic Engineering & Biotechnology News

Novartis has agreed to license Sangamo Therapeutics zinc finger protein transcription factors (ZFP-TFs) to develop gene regulation therapies for neurodevelopmental disorders that include autism spectrum disorder and intellectual disability, the companies said, through a collaboration that could generate more than $795 million for Sangamo.

Through Sangamos ZFP-TFs, the companies plan over three years to develop treatments addressing three target genes associated with neurodevelopmental disorders, by upregulating the expression of key genes that are inadequately expressed in individuals with certain neurodevelopmental disorders.

The goal is to create new gene regulation therapies that act at the genomic level, moving us beyond the symptom focused treatments of today and toward therapies that can address some of the most challenging neurodevelopmental disorders, Jay Bradner, president of the Novartis Institutes for BioMedical Research, said in a statement. This collaboration with Sangamo is part of our commitment to pioneering the next generation of neurodevelopmental treatments.

Sangamos ZFP-TF genome regulation technology, now delivered via adeno-associated viruses (AAVs), is designed to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect, at the DNA level.

While AAVs have many advantages that make them well-suited for gene therapy, Novartis says, they also have one disadvantage: They cant carry large genes. The collaboration is designed to enable the companies to target diseases caused by mutations in one copy of a large gene.

The gene for a ZFP-TF is small enough to fit inside an AAV, Ricardo Dolmetsch, head of neuroscience at the Novartis Institutes for BioMedical Research, explained in a post on the companys blog. We can use it to increase the production of a large gene in someone who still has one intact copy of the gene. This dramatically expands the range of diseases that we can potentially target with gene therapy because many diseases are caused by the loss of a single copy of a gene.

Each of Sangamos ZFP-TFs is engineered to bind to a target region of genomic DNA in a highly specific and selective manner. They can be designed to precisely modulate the expression of targeted genes to varying extents. After identifying its target, the ZFP-TF recruits other proteins that help switch genes on or off.

The zinc finger nuclease technology is remarkable, Macrae told GEN in January. Its one of the commonest transcripts in the body. Its natural and human, and its very, very adaptable. The individual units are modular, so one is always able to come up with a solution for any part of the genome.

For its part, Sangamo reasons that it can engineer zinc finger proteins to address virtually any genomic target.

We are building a broad pipeline of wholly owned and partnered programs with the goal to bring our genomic medicines to patients, stated Sangamo CEO Sandy Macrae. In the case of the central nervous system, there are potentially hundreds of neurological disease gene targets that may be addressable by our zinc finger platform.

For Sangamo, the collaboration with Novartis is the second signed this year that focuses on applying ZFP-TFs toward treating neurological disorders. In February, Sangamo launched a potentially more than $2.7 billion partnership to develop and commercialize Sangamo gene regulation therapies. The collaboration included ST-501 for tauopathies including Alzheimers disease, ST-502 for synucleinopathies including Parkinsons disease, a third treatment targeting an undisclosed neuromuscular disease target, and additional treatments for up to nine additional undisclosed neurological disease targets over five years.

In its latest partnership with Novartis, the Swiss pharma giant will have exclusive rights to ZFP-TFs targeting the genes, which are undisclosed, during the three-year collaboration period.

Novartis also has the option to license Sangamos AAVs. Sangamo has agreed to oversee specified research and associated manufacturing activities, all of which will be funded by Novartiswhile Novartis agreed to oversee additional research activities, investigational new drug-enabling studies, clinical development, related regulatory interactions, manufacturing, and global commercialization.

Novartis agreed to pay Sangamo a $75 million upfront license fee within 30 days, plus up to $720 million tied to achieving development and commercial milestonesconsisting of up to $420 million in development milestones and up to $300 million in commercial milestones.

Sangamo is also eligible to receive from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.

Partnering Sangamos proprietary technology with Novartis deep experience in neuroscience drug development is a powerful combination which expands Sangamos pipeline and allows us to tackle challenging neurodevelopmental conditions, Macrae added.

More here:

Novartis Taps Sangamo Zinc Finger Tech for Gene Regulation Therapies - Genetic Engineering & Biotechnology News

Inside the battle to save the banana – Marketplace

While international spotlight is on the spread of COVID-19, theres another pathogen that scientists arestruggling to contain: tropical race 4, or Panama disease. It doesnt threaten human life but its endangering what the United Nations has deemed the worlds fourth most important food crop: the banana.

A startup in the English city of Norwich is leading the fight to save the banana from this disease.

We are changing the banana genetics to make it more resistant to Panama disease and other diseases, said Gilad Gershon, CEO of Tropic Biosciences, on a recent tour of the companys laboratory.

For 20 years, Panama disease a fungal infection has been spreading across the tropics. Last year it surfaced in Latin America, where most of the worlds bananas for exportare grown. Worldwide, banana exports have been valued at about $13 billion a year

The industry already lives on a very low margin and any disruption of that could have a catastrophiceffect for the industry and the major players in it, Gershon said.

Tropic Biosciences is editing out the genes that make the banana vulnerable to the disease. Gene editing is likely to be met with less resistance from international consumers and regulators than genetic modification, which involves adding DNA of different organisms.

People may be happier about gene editing because it doesnt introduce new genes, said Dr. Dan Bebber, a plant expert at Exeter University.

Nevertheless, the gene editing procedure has fallen foul of the European Unions anti-genetic modification regulations and therefore Tropic Biosciences bananas would be barred from sale in the EU.

Europe accounts for about 30% of global imports. Its a big chunk of the market, conceded Gershon. But this is the reality we have to live with. And theres a very big world outside Europe; 70% of the market is available to us.

Genetic engineering is not the only way to save the banana.Dr. Bebber, who leads an initiative investigating the resilience of banana production and supply, the BananaEx Project, points out that the export trade is particularly vulnerable because it relies on a single strain of the fruit, the Cavendish, which is particularly susceptible to Panama Disease.

We need to think about the diversity of the plants were growing. And there are scientific research groups around the world looking at breeding new types of bananas, as well as the other approaches like gene editing, said Dr. Bebber.

With big money at stake, Tropic Biosciences wont be the only contestant in the race to save the banana. But it will hold its first field trials later this year and plans to have its banana seeds that are resistant to Panama Disease on the market within four years.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today in any amount to become a Marketplace Investor. Now more than ever, your commitment makes a difference.

Go here to read the rest:

Inside the battle to save the banana - Marketplace

New Cuban drug with very encouraging results against COVID-19 – OnCubaNews

The Cuban drug known so far as CIGB-300 is showing very encouraging results against COVID-19 in its first phase of clinical evaluation, according to the official media.

The antiviral-action drug was designed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, and is being studied as part of the research being carried out by Cuban science to confront the pandemic, the BioCubaFarma business group said on Facebook.

Las investigaciones no se detienen en @BioCubaFarma, nuevos medicamentos se evalan para la enfermedad #COVID19. Un

Posted by Biocubafarma onSaturday, August 1, 2020

With previously demonstrated antitumor efficacy, the CIGB-300 is the subject of a controlled clinical trial that started last May in patients positive for SARS-CoV-2, pointed out Cubadebate, which doesnt offer conclusive or preliminary statistics about the trial.

The study seeks to find out the efficacy of this drug against the SARS-CoV-2 coronavirus, following the steps of research carried out with other drugs, which have also had good results.

In total, the CIGB is currently working on 16 lines of research related to the treatment and control of COVID-19, according to Dr. Gerardo Guilln, director of biomedical research at the renowned scientific institution.

Cuba inaugurates plant to produce drug against COVID-19

A few days ago a synthetic peptides production plant was inaugurated at the CIGB, which is already producing a drug successfully used as part of the Cuban medical protocol against coronavirus.

The role of Cuban science, and in particular of its prestigious biotechnology industry, has been fundamental in confronting the epidemic on the island. Several of its products, including Jusvinza or CIGB-258, the recombinant interferon alpha 2bboth CIGB, and Itolizumab, have shown their effectiveness in different stages of the disease.

Original post:

New Cuban drug with very encouraging results against COVID-19 - OnCubaNews

Feeding the World with Genetic Technologies: Technologies and Policies – IDTechEx.com

Genetic Technologies in Agriculture 2020-2030: Forecasts, Markets, Technologies

Genome editing (CRISPR, TALENs, ZFNs), Transgenics (GMOs), Synthetic Biology, and Breeding in Crop Agriculture: Technology and Market Analysis

By Dr Michael Dent

21st century agriculture is facing some major challenges. The global population is set to increase to over 10 billion by 2050, something the UN estimates will require a 70% from today's global food production. At the same, resources are dwindling - the loss of agricultural land stemming from climate change and urbanisation coupled with plateauing crop yields will present major challenges to every nation on Earth.

Genetic technologies in agriculture 2020-2030, a new report from IDTechEx, explores the use of biotechnology as a potential solution to these challenges. The report provides in-depth technical and market insight into the different genetic technologies used in crop agriculture, including transgenics (GMOs), genome editing techniques (CRISPR, TALENs, ZFNs, etc.) and breeding strategies, while also exploring the regulatory and industrial landscapes in which they operate. The report forecasts the future of the industry over the next decade, identifying genome editing technologies as a key growth area.

This is not the first time that world has faced a food crisis This is not the first time that the world has faced a food crisis due to plateauing yields and growing populations. In the 1960s, famine threatened much of Asia, with Paul Ehrlich's 1968 bestseller "The Population Bomb" predicting that famines centred in India would kill hundreds of millions across the following decades.

This bleak future was mostly avoided, largely thanks to the Green Revolution. Using selective breeding, American biologist Norman Borlaug created a high yield strain of wheat that led to more grain per acre, significantly boosting Mexico's agricultural output. Soon, similar strategies were used in India to develop high yield IR8 rice. These selective breeding strategies, alongside advances in fertiliser and mechanisation technologies led to a boom in global food production, with cereal production in Asia doubling between 1970 and 1995.

Selective breeding is just one of many techniques for manipulating the DNA of plants in agriculture to create improved seeds and traits. Over the past few decades, the genetic engineering tools available to scientists has expanded to include methods such as mutagenesis and transgenic breeding, the technique used to develop "genetically modified organisms" (GMOs). However, in recent years, technological advances such as next generation DNA sequencing and gene editing techniques such as TALENs, ZFNs and CRISPR-Cas9 have vastly expanded the capabilities of genetic engineering. This has led to much excitement in the field of agricultural biotechnology, with proponents hoping that modern genetic technologies could help usher in a new Green Revolution of agricultural productivity. Synthetic biology and manipulation of the crop microbiome could open a huge window of opportunities for boosting yields in previously inaccessible ways.

The report assesses the following:

Read the original:

Feeding the World with Genetic Technologies: Technologies and Policies - IDTechEx.com

Bannon Calls for Ban on Nike and Apple Products in the United States – Corporate Crime Reporter

Steve Bannon took to the airwaves yesterday on his daily show War Room: Pandemic and called for a ban on all Nike and Apple products in the United States.

Nike and Apples products should be banned in the United States of America, Bannon said. Woke Nike and Woke Apple are using slave labor in China. Their wokeness is a head fake and a diversion. Their business model is based upon the back breaking forced slave labor costs in China. Thats why their margins are so high. (Apple CEO) Tim Cook is the biggest phony in the world. The guys at Nike are the biggest phonies in the world. Look at the people you are stealing from. . . .Woke Apple that the Republicans and certain people in the Trump administration kowtow to, using slave labor.

Bannon reprimanded Congressional Republicans for arguing that to stand up to China, weve got to keep the concentration of power in these tech companies.

Its exactly the opposite, Bannon said. That is a bald faced lie. The last thing we need is more empowerment of these tech companies. They are not interested in a fight with the Chinese Communist Party. These companies are all in business with the Chinese Communist Party. Its outrageous to use this as an excuse.

In another segment of his show yesterday, Bannon brought up an op-ed that ran in the Wall Street Journal earlier this week titled How to Hold Beijing Accountable for the Coronavirus Why did China cover up the epidemic? The most plausible explanation involves a Wuhan lab, by Jamie Metzl.

Metzl served in the National Security Council and State Department in the Clinton administration. He is a senior fellow of the Atlantic Council, a member of the WHO international advisory committee on human genome editing, and author of Hacking Darwin: Genetic Engineering and the Future of Humanity.

To ensure everyones safety, the WHO and outside investigators must be empowered to explore all relevant questions about the origins of the pandemic without limits, Metzl wrote. This comprehensive forensic investigation must include full access to all of the scientists, biological samples, laboratory records and other materials from the Wuhan virology institutes and other relevant Chinese organizations.

Denying that access should be considered an admission of guilt by Beijing, Metzl concluded.

On his podcast, Bannon read that portion of the op-ed and then said Beijing is not just going to turn over the relevant information.

Give them 72 hours to turn over everything, Bannon said. Then you drop the hammer on them. You sanction the banks. You sanction the individuals. You cut them off from the dollar. The only thing they understand is smash mouth.

See more here:

Bannon Calls for Ban on Nike and Apple Products in the United States - Corporate Crime Reporter